With the market in general, currently yes although a 300M cap ain't bad for OTC. With the Big Pharma agreements behind the scenes, no. With the leading trial centers, no. With the pipeline and platforms, no. I sense the former is rapidly changing to a no also and quickly....................
whoops this is just "star gazing" on my part but i don't think we have a cred problem but a "bare knuckle brawler" situation. you would have to be deaf, blind and crazy not to know about kevetrin if you are in oncology imo. i think leo is being approached with what he considers low ball nose under the tent proposals and he is telling them to get lost. if he had a board this would have to be made known to us therefore leo keeps talking, talking about a board.
Market Data 
Markets 
AI
